Page last updated: 2024-09-05

anidulafungin and Aspergillosis

anidulafungin has been researched along with Aspergillosis in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (6.00)	18.2507
2000's	20 (40.00)	29.6817
2010's	26 (52.00)	24.3611
2020's	1 (2.00)	2.80

Authors

Authors	Studies
Alastruey-Izquierdo, A; Cuenca-Estrella, M; Lass-Flörl, C; Perkhofer, S; Rodriguez-Tudela, JL	1
Arendrup, MC; Bruun, B; Buzina, W; Garcia-Effron, G; Jensen, HE; Lass-Flörl, C; Lundin, C; Mortensen, KL; Perlin, DS; Reiter, N	1
Abastabar, M; Alastruey-Izquierdo, A; Hedayati, MT; Meletiadis, J; Nouripour-Sisakht, S; Rivero-Menendez, O; Sabino, R; Seyedmousavi, S; Siopi, M; Tavakoli, M; Valadan, R; van der Lee, H; Yazdani Charati, J; Zarrinfar, H	1
Denis, J; Herbrecht, R; Ledoux, MP; Toussaint, E	1
Brock, M; Galiger, C; Ibrahim-Granet, O; Jouvion, G; Parlato, M; Savers, A	1
Bleeker-Rovers, CP; Delsing, CE; Frager, FA; Gresnigt, MS; Kox, M; Kullberg, BJ; Leentjens, J; Monneret, G; Netea, MG; Pachot, A; Pickkers, P; Preijers, F; van de Veerdonk, FL; Venet, F	1
Liu, P; Mould, DR	2
Bow, EJ; Cornely, OA; Heinz, WJ; Herbrecht, R; Jagannatha, S; Koh, LP; Kontoyiannis, DP; Lee, DG; Maertens, JA; Marr, KA; Nucci, M; Pappas, PG; Queiroz-Telles, F; Rottinghaus, ST; Schlamm, HT; Selleslag, D; Slavin, MA; Walsh, TJ; Wingard, JR	1
Cotton, D	1
Capilla, J; Guarro, J; Mayayo, E; Pastor, FJ; Sanchis, M	1
Gökbolat, E; Ilkit, M; Kiraz, N; Öz, Y; Özdemir, HG; Seyedmousavi, S	1
Akoumianaki, T; Albert, N; Andrianaki, A; Chamilos, G; Ioannou, P; Kontoyiannis, DP; Kyrmizi, I; Perlin, D; Samonis, G	1
Castanheira, M; Jones, RN; Messer, SA; Pfaller, MA; Rhomberg, PR	1
Balkovec, JM; Bartizal, K; Hough, G; James, KD; Krishnan, BR; Ong, V; Schlosser, M	1
Capilla, J; Guarro, J; Martin-Vicente, A	1
Cuenca-Estrella, M; Gurguí, M	1
Aguado, JM; Ayats, J	1
Ruiz Camps, I; Vázquez López, L	1
Barchiesi, F; Loretelli, C; Manso, E; Milici, ME; Orlando, F; Pisa, E; Santinelli, A; Scalise, G; Spreghini, E	1
Boyken, L; Diekema, DJ; Hollis, RJ; Kroeger, J; Messer, SA; Pfaller, MA; Tendolkar, S	1
Balcer, HE; Chahine, EB; Sucher, AJ	1
Gullo, A	1
Bal, AM	1
Kuti, EL; Kuti, JL	1
Calvo, E; Guarro, J; Mayayo, E; Pastor, FJ; Salas, V	2
Tapısız, A	1
Hou, J; Kontoyiannis, DP; Lewis, RE; Liao, G; Prince, RA	1
Le Guyader, N; Leverger, G	1
George, J; Reboli, AC	1
Andes, DR; Baddley, JW; Chiller, T; Ito, JI; Kauffman, CA; Kontoyiannis, DP; Lockhart, SR; Marr, KA; Pappas, PG; Walsh, TJ; Zimbeck, AJ	1
Calvo, E; Guarro, J; Mayayo, E; Pastor, FJ	1
Fortún, J	1
Brüggemann, RJ; Melchers, WJ; Mouton, JW; Seyedmousavi, S; Verweij, PE	1
Brüggemann, RJ; Melchers, WJ; Mouton, JW; Rijs, AJ; Seyedmousavi, S; Verweij, PE	1
Bernal, S; Chávez M, M; Claro, RM; Martín-Mazuelos, E; Pemán, J; Ramirez, M; Serrano, Mdel C; Valverde-Conde, A	1
Dowell, JA; Henkel, T; Knebel, W; Krause, D; Ludden, T; Stogniew, M	1
Murdoch, D; Plosker, GL	1
Morris, MI; Villmann, M	1
Cornely, OA; Karthaus, M; Kümmerle, T; Vehreschild, JJ	1
Khachikian, D; Kim, R; Reboli, AC	1
Guarro, J; Pastor, FJ	1
Denning, DW; Morrissey, G; Morrissey, J; Oakley, KL; Verweij, PE	1
Bacher, J; Bell, A; Callender, DP; Groll, AH; McMillian, CL; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ	1
Clemons, KV; Sobel, RA; Stevens, DA	1
Andriole, VT; Marino, S; Roberts, J; Schock, K	1
Bacher, JS; Groll, AH; Lyman, CA; Mickiene, D; Petraitiene, R; Petraitis, V; Piscitelli, SC; Walsh, TJ	1
Graybill, JR	1

Reviews

14 review(s) available for anidulafungin and Aspergillosis

Article	Year
[Current status of invasive fungal infections. New diagnostic techniques and antifungal agents]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 14 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; beta-Glucans; Candidiasis; Clinical Trials as Topic; Critical Care; Diabetes Complications; Disease Susceptibility; Echinocandins; Fungemia; Galactose; Hematologic Diseases; Humans; Immunocompromised Host; Mannans; Meta-Analysis as Topic; Mycoses; Neoplasms; Opportunistic Infections	2008
[Role of anidulafungin in solid organ transplant recipients]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 14 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Drug Interactions; Echinocandins; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney; Liver; Organ Transplantation; Postoperative Complications; Premedication; Risk Factors	2008
[Potential of anidulafungin in hematological patients]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 14 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Azoles; Candidiasis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Echinocandins; Fungemia; Hematologic Diseases; Hematologic Neoplasms; Humans; Inactivation, Metabolic; Kidney Diseases; Liver Diseases; Mice; Neutropenia; Risk Factors	2008
Echinocandins: the newest class of antifungals. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:10 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Child; Clinical Trials as Topic; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Mycoses	2009
Invasive fungal infections: the challenge continues. Drugs, 2009, Volume: 69 Suppl 1 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candida; Candidiasis; Drug Therapy, Combination; Echinocandins; Humans; Mycoses; Risk Factors	2009
The echinocandins: three useful choices or three too many? International journal of antimicrobial agents, 2010, Volume: 35, Issue:1 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Caspofungin; Clinical Trials as Topic; Echinocandins; Humans; Lipopeptides; Micafungin	2010
Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:10 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Drug Interactions; Echinocandins; Humans; Mycoses	2010
Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:3 Topics: Adult; Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis, Invasive; Child; Drug Interactions; Drug Resistance, Fungal; Drug Therapy, Combination; Echinocandins; Humans	2011
Anidulafungin: when and how? The clinician's view. Mycoses, 2012, Volume: 55, Issue:1 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Drug Resistance, Fungal; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Humans; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole	2012
[Antifungal therapy update: new drugs and medical uses]. Enfermedades infecciosas y microbiologia clinica, 2011, Volume: 29 Suppl 5 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Early Diagnosis; Echinocandins; Humans; Immunocompromised Host; Lipopeptides; Micafungin; Mycoses; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome; Triazoles	2011
Echinocandins in the management of invasive fungal infections, Part 2. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Oct-01, Volume: 63, Issue:19 Topics: Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Catheterization; Critical Care; Drug Therapy, Combination; Echinocandins; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Transplants	2006
Anidulafungin--state of affairs from a clinical perspective. Mycoses, 2007, Volume: 50 Suppl 1 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Disease Models, Animal; Drug Interactions; Echinocandins; Humans; Rabbits	2007
A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:10 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Caspofungin; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Echinocandins; Enzyme Inhibitors; Glucosyltransferases; Humans; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Treatment Outcome	2007
[Anidulafungin: experimental therapy of fungal infections in animal models]. Revista iberoamericana de micologia, 2008, Volume: 25, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Disease Models, Animal; Echinocandins; Lung Diseases, Fungal	2008

Trials

4 trial(s) available for anidulafungin and Aspergillosis

Article	Year
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC infectious diseases, 2014, Mar-26, Volume: 14 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis, Invasive; Combined Modality Therapy; Echinocandins; Female; Humans; Immunotherapy; Interferon-gamma; Male; Middle Aged; Prospective Studies; Recombinant Proteins	2014
Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus; Biological Availability; Body Weight; Double-Blind Method; Drug Administration Schedule; Echinocandins; Female; Half-Life; Humans; Injections, Intravenous; Male; Middle Aged; Models, Statistical; Prospective Studies; Voriconazole	2014
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Annals of internal medicine, 2015, Jan-20, Volume: 162, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Aspergillosis; Double-Blind Method; Drug Therapy, Combination; Echinocandins; Female; Galactose; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Male; Mannans; Middle Aged; Platelet Count; Treatment Outcome; Voriconazole; Young Adult	2015
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. Journal of clinical pharmacology, 2004, Volume: 44, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis; Drug Interactions; Echinocandins; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Monte Carlo Method; Peptides, Cyclic; Racial Groups; Sex Factors	2004

Other Studies

32 other study(ies) available for anidulafungin and Aspergillosis

Article	Year
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2 Topics: Antifungal Agents; Aspergillosis; Aspergillus; DNA, Fungal; Humans; Microbial Sensitivity Tests; Soil Microbiology	2009
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Echinocandins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Lipopeptides; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Polymerase Chain Reaction	2009
Genetic diversity and antifungal susceptibility patterns of Aspergillus nidulans complex obtained from clinical and environmental sources. Mycoses, 2020, Volume: 63, Issue:1 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus fumigatus; Aspergillus nidulans; Azoles; Cross Infection; Environmental Microbiology; Genetic Variation; Greece; Humans; Iran; Micafungin; Microbial Sensitivity Tests; Microsatellite Repeats; Molecular Epidemiology; Netherlands; Phylogeny; Phylogeography; Portugal; Spain; Tubulin	2020
New pharmacological opportunities for the treatment of invasive mould diseases. The Journal of antimicrobial chemotherapy, 2017, 03-01, Volume: 72, Issue:suppl_1 Topics: Amphotericin B; Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Drug Therapy, Combination; Echinocandins; Humans; Invasive Fungal Infections; Mucormycosis; Nitriles; Pyridines; Triazoles; Voriconazole	2017
Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Echinocandins; Luminescent Measurements; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole	2013
Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus; Biological Availability; Chemical and Drug Induced Liver Injury; Double-Blind Method; Drug Administration Schedule; Echinocandins; Female; Half-Life; Hallucinations; Humans; Male; Middle Aged; Models, Statistical; Photophobia; Prospective Studies; Voriconazole	2014
Celebrating the ACP centennial: from the annals archive. Annals of internal medicine, 2015, Jan-20, Volume: 162, Issue:2 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Echinocandins; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Voriconazole	2015
Experimental efficacy of anidulafungin against Aspergillus terreus species complex. Medical mycology, 2015, Volume: 53, Issue:6 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Disease Models, Animal; Echinocandins; Humans; Kidney; Mice	2015
Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses. Mycopathologia, 2016, Volume: 181, Issue:3-4 Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Echinocandins; Eye; Eye Infections, Fungal; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Triazoles; Voriconazole	2016
Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae. Antimicrobial agents and chemotherapy, 2015, Dec-07, Volume: 60, Issue:3 Topics: Albumins; Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Culture Media; Echinocandins; Humans; Hyphae; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Voriconazole	2015
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:10 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Aspergillus flavus; Aspergillus fumigatus; Candida; Candida glabrata; Candidiasis; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Half-Life; Humans; Lipopeptides; Microbial Sensitivity Tests	2016
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:11 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Biotransformation; Blood Proteins; Candidiasis; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Echinocandins; Female; Humans; Inactivation, Metabolic; Macaca fascicularis; Male; Microbial Sensitivity Tests; Microsomes, Liver; Rats, Sprague-Dawley	2016
Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis. Medical mycology, 2017, Jun-01, Volume: 55, Issue:4 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Echinocandins; Kidney; Male; Mice; Survival Analysis; Triazoles	2017
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Brain; Drug Therapy, Combination; Echinocandins; Kidney; Mice; Microbial Sensitivity Tests	2009
In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. Journal of clinical microbiology, 2009, Volume: 47, Issue:10 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Echinocandins; Humans; Inhibitory Concentration 50; Lipopeptides; Micafungin; Microbial Sensitivity Tests	2009
In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:3 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Echinocandins; Male; Mice	2011
Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Caspofungin; Disease Models, Animal; Drug Resistance, Fungal; Echinocandins; Lipopeptides; Mice; Mice, Inbred BALB C; Treatment Outcome	2011
[Echinocandins in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011, Volume: 18 Suppl 1 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candidiasis, Invasive; Caspofungin; Child; Echinocandins; Evidence-Based Medicine; Humans; Injections, Intravenous; Lipopeptides; Micafungin; Mycoses; Treatment Outcome	2011
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:8 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Transplantation	2011
Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo. International journal of antimicrobial agents, 2011, Volume: 38, Issue:4 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus niger; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Echinocandins; Male; Mice; Microbial Sensitivity Tests; Survival Rate; Treatment Outcome	2011
Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus. Mycopathologia, 2012, Volume: 173, Issue:4 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Drug Therapy, Combination; Echinocandins; Humans; Male; Mice; Pyrimidines; Triazoles; Voriconazole	2012
Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1 Topics: Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus fumigatus; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Echinocandins; Female; Fungal Proteins; Humans; Mice; Mutation; Neutrophils; Promoter Regions, Genetic; Pyrimidines; Survival Analysis; Treatment Outcome; Triazoles; Voriconazole	2013
Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Resistance, Fungal; Drug Synergism; Drug Therapy, Combination; Echinocandins; Female; Mice; Pyrimidines; Survival Analysis; Treatment Outcome; Triazoles; Voriconazole	2013
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagnostic microbiology and infectious disease, 2003, Volume: 45, Issue:2 Topics: Amphotericin B; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Echinocandins; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Pyrimidines; Time Factors; Triazoles; Voriconazole	2003
Anidulafungin. Drugs, 2004, Volume: 64, Issue:19 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cell Wall; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation, Preclinical; Echinocandins; Esophageal Diseases; Glucosyltransferases; Humans; Infusions, Intravenous; Injections, Intravenous; Molecular Structure; New Zealand; Peptides, Cyclic; Time Factors; Treatment Outcome	2004
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:4 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count, Microbial; Cyclophosphamide; Drug Resistance, Microbial; Echinocandins; Immunocompromised Host; Immunosuppressive Agents; Male; Mice; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic	1998
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:11 Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Dose-Response Relationship, Drug; Echinocandins; Female; Lung Diseases, Fungal; Neutropenia; Peptides, Cyclic; Rabbits	1998
LY 303366. ECB. Drugs in R&D, 1999, Volume: 1, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis, Vulvovaginal; Drugs, Investigational; Echinocandins; Female; Fungi; Humans; Male; Mycoses; Peptides, Cyclic; Pneumocystis Infections; Rats	1999
Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Disease Models, Animal; Drug Interactions; Echinocandins; Glucocorticoids; Male; Mice; Mice, Inbred DBA; Peptides, Cyclic	2000
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:12 Topics: Anidulafungin; Animals; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Brain; Disease Models, Animal; Echinocandins; Liver; Lung; Peptides, Cyclic; Rabbits; Thiazoles; Triazoles	2000
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10 Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Disease Models, Animal; Echinocandins; Female; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Peptides, Cyclic; Rabbits; Tissue Distribution	2001
The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? International journal of clinical practice, 2001, Volume: 55, Issue:9 Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cell Wall; Echinocandins; Fungi; Glucans; Humans; Lipopeptides; Lipoproteins; Micafungin; Peptides; Peptides, Cyclic; Randomized Controlled Trials as Topic	2001